Berberine and Adiposity in Diabetes-Free Individuals With Obesity and MASLD
JAMA Network Open · 16.01.2026 · 9 (1) · e2554152
DOI: 10.1001/jamanetworkopen.2025.54152 ↗Kurz gefasst
Klinische Studie (Phase IV) in der Zeitschrift JAMA Network Open, online erschienen am 16.01.2026. Verfasst von Lubi Lei und 16 weiteren Autor:innen. Beteiligte Einrichtung: National Clinical Research Center for Cardiovascular Diseases, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medica…. Hauptthemen laut MEDLINE: Adiposity, Berberine, Fatty Liver, Obesity. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Importance Berberine is a potential therapy for metabolic disorders, yet its effects on visceral adipose tissue (VAT) and liver fat remain uncertain.
Objectives
To evaluate the efficacy and safety of berberine in reducing VAT area and liver fat content in diabetes-free individuals with obesity and metabolic dysfunction–associated steatotic liver disease (MASLD). Design, Setting, and Participants In this multicenter, double-blind randomized clinical trial, diabetes-free individuals with obesity and MASLD were enrolled at 11 hospitals in China between July 6 and December 29, 2023, with a follow-up duration of 6 months.
Interventions
Participants were randomly assigned to receive either oral berberine, 1 g/d, or a matching placebo. Main Outcomes and Measures The primary outcomes were relative percentage change in VAT area and absolute change in liver fat content assessed by computed tomography. Other outcomes included changes in parameters of glucose, lipids, and inflammation. Analyses were conducted according to the intention-to-treat principle.
Results
Among 337 randomized participants (mean [SD] age, 41.8 [10.6] years; 221 [65.6%] male), 169 received berberine and 168 placebo. The mean (SD) medication adherence rates were 90.3% (14.7%) for berberine and 90.7% (17.4%) for placebo. No significant differences were observed between study arms for VAT area (1.4% [97.5% CI, −2.4% to 5.2%]) or liver fat content (0.9% [97.5% CI, −0.4% to 2.1%). Berberine was associated with larger reductions in low-density lipoprotein cholesterol (−7.72 [95% CI, −13.13 to −1.93] mg/dL), apolipoprotein B (−3.42 [95% CI, −6.33 to −0.51] mg/dL) and high-sensitivity C-reactive protein (hs-CRP) (−0.072 [95% CI, −0.140 to −0.004] mg/dL) vs placebo, but not other secondary outcomes. The incidence of adverse events was similar between study arms. Post hoc analyses suggested consistent patterns of larger reductions in low-density lipoprotein cholesterol, apolipoprotein B, and hs-CRP levels in participants with higher baseline hs-CRP levels. Conclusions and Relevance In this randomized clinical trial of diabetes-free individuals with obesity and MASLD, a 6-month berberine treatment at a daily dose of 1 g had an excellent safety profile but did not reduce VAT area or liver fat content. Trial Registration ClinicalTrials.gov Identifier: NCT05647915
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- National Clinical Research Center for Cardiovascular Diseases, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
- Lifecycle Health Management Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
- Department of Virology, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
- Department of Radiology, Beijing Jishuitan Hospital, Beijing, China.
- Clinical Research Institute, Institute of Advanced Clinical Medicine, Peking University, Beijing, China.
Zitieren
APA
Lei, L., Wang, B., Zhao, L., Li, J., Yan, X., Jiang, J., Wang, L., Ren, G., Li, Y., Cheng, X., Yan, X., Zhu, Y., Guo, Y., Zhong, H., Zhang, H., Li, J., & BRAVO Collaborative Group (2026). Berberine and Adiposity in Diabetes-Free Individuals With Obesity and MASLD. JAMA Network Open, 9(1), e2554152. https://doi.org/10.1001/jamanetworkopen.2025.54152
Vancouver
Lei L, Wang B, Zhao L, Li J, Yan X, Jiang J, et al. Berberine and Adiposity in Diabetes-Free Individuals With Obesity and MASLD. JAMA Network Open. 2026;9(1):e2554152. doi:10.1001/jamanetworkopen.2025.54152
BibTeX
@article{Lei2026,
author = {Lei, Lubi and Wang, Bin and Zhao, Lingshan and Li, Jingkuo and Yan, Xiaofang and Jiang, Jiandong and Wang, Lulu and Ren, Gang and Li, Yinchu and Cheng, Xiaoguang and Yan, Xiaoyan and Zhu, Yidan and Guo, Yuanlin and Zhong, Hui and Zhang, Haibo and Li, Jing and BRAVO Collaborative Group, BRAVO Collaborative Group},
title = {Berberine and Adiposity in Diabetes-Free Individuals With Obesity and MASLD},
journal = {JAMA Network Open},
year = {2026},
volume = {9},
number = {1},
pages = {e2554152},
doi = {10.1001/jamanetworkopen.2025.54152}
}
EUVIMED